ID   LC-2/ad
AC   CVCL_1373
SY   LC-2-Ad; LC-2-ad; LC-2 ad; LC2/Ad; LC2/AD; LC2AD
DR   BTO; BTO:0006466
DR   CLO; CLO_0037020
DR   CLO; CLO_0050073
DR   EFO; EFO_0003140
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472314
DR   cancercelllines; CVCL_1373
DR   Cell_Model_Passport; SIDM00297
DR   ChEMBL-Cells; CHEMBL3308545
DR   ChEMBL-Targets; CHEMBL2366260
DR   Cosmic; 907786
DR   Cosmic; 946052
DR   Cosmic; 1154602
DR   Cosmic; 1571726
DR   Cosmic; 1656903
DR   Cosmic; 1995480
DR   Cosmic-CLP; 907786
DR   DepMap; ACH-002157
DR   ECACC; 94072247
DR   EGA; EGAS00001000978
DR   GDSC; 907786
DR   GEO; GSM1670043
DR   IARC_TP53; 21470
DR   LINCS_LDP; LCL-1667
DR   PharmacoDB; LC2ad_831_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1373
DR   RCB; RCB0440
DR   Wikidata; Q54902124
RX   PubMed=8291444;
RX   PubMed=8348978;
RX   PubMed=16105816;
RX   PubMed=20164919;
RX   PubMed=22313637;
RX   PubMed=23154560;
RX   PubMed=23578175;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 58 hours (Note=At 32th passage) (PubMed=8291444).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (PubMed=23578175).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.51%; Native American=0.63%; East Asian, North=76.2%; East Asian, South=13.98%; South Asian=0.14%; European, North=0.91%; European, South=4.65% (PubMed=30894373).
CC   Caution: Indicated to have a EGFR p.Leu858Arg (c.2573T>G) mutation according to PubMed=16105816) but this is in contradiction of results of exome sequencing in CCLE and Cosmic-CLP.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; ECACC; RCB
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,12
ST   D16S539: 9
ST   D5S818: 10
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 16,19
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=8291444; DOI=10.1111/j.1440-1827.1993.tb03232.x;
RA   Kataoka H., Itoh H., Seguchi K., Koono M.;
RT   "Establishment and characterization of a human lung adenocarcinoma
RT   cell line (LC-2/ad) producing alpha 1-antitrypsin in vitro.";
RL   Acta Pathol. Jpn. 43:566-573(1993).
//
RX   PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R;
RA   Kataoka H., Seguchi K., Inoue T., Koono M.;
RT   "Properties of alpha 1-antitrypsin secreted by human adenocarcinoma
RT   cell lines.";
RL   FEBS Lett. 328:291-295(1993).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=23154560; DOI=10.1097/JTO.0b013e3182721ed1;
RA   Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T.,
RA   Sakatani T., Oguni S., Tamura T., Kataoka H., Endo S., Murakami Y.,
RA   Aburatani H., Fukayama M., Niki T.;
RT   "Identification of CCDC6-RET fusion in the human lung adenocarcinoma
RT   cell line, LC-2/ad.";
RL   J. Thorac. Oncol. 7:1872-1876(2012).
//
RX   PubMed=23578175; DOI=10.1111/cas.12175;
RA   Suzuki M., Makinoshima H., Matsumoto S., Suzuki A., Mimaki S.,
RA   Matsushima K., Yoh K., Goto K., Suzuki Y., Ishii G., Ochiai A.,
RA   Tsuta K., Shibata T., Kohno T., Esumi H., Tsuchihara K.;
RT   "Identification of a lung adenocarcinoma cell line with CCDC6-RET
RT   fusion gene and the effect of RET inhibitors in vitro and in vivo.";
RL   Cancer Sci. 104:896-903(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//